AstraZeneca PLC
AZN
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
E: ir@astrazeneca.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
Stocks News & Analysis
markets
What are emerging and frontier markets?
Power blocs, frontier stocks and investor shocks explained as the world becomes more complex
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks
Best international companies to own: 2023 Edition
These companies from various corners of the globe are well positioned for the future.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,796.00 | 23.70 | -0.27% |
| CAC 40 | 7,741.07 | 34.83 | -0.45% |
| DAX 40 | 23,714.20 | 234.70 | -0.98% |
| Dow JONES (US) | 42,865.77 | 1.10 | -0.00% |
| FTSE 100 | 8,859.11 | 5.24 | -0.06% |
| HKSE | 24,035.38 | 331.56 | -1.36% |
| NASDAQ | 19,615.88 | 99.11 | -0.50% |
| Nikkei 225 | 38,173.09 | 248.10 | -0.65% |
| NZX 50 Index | 12,649.10 | 43.17 | 0.34% |
| S&P 500 | 6,022.24 | 16.57 | -0.27% |
| S&P/ASX 200 | 8,565.10 | 27.00 | -0.31% |
| SSE Composite Index | 3,402.66 | 0.34 | 0.01% |